Analyzing Pulse Biosciences (NASDAQ:PLSE) and Covalon Technologies (OTCMKTS:CVALF)

Profitability

This table compares Covalon Technologies and Pulse Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Covalon Technologies	10.95%	13.40%	11.59%
Pulse Biosciences	N/A	-68.44%	-58.17%

Insider and Institutional Ownership

77.0% of Pulse Biosciences shares are held by institutional investors. 71.5% of Pulse Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Covalon Technologies and Pulse Biosciences”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Covalon Technologies	$22.91 million	2.17	$1.96 million	$0.09	20.11
Pulse Biosciences	$700,000.00	1,450.15	-$53.58 million	N/A	N/A

Covalon Technologies has higher revenue and earnings than Pulse Biosciences.

Risk and Volatility

Covalon Technologies has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500.

Summary

Covalon Technologies beats Pulse Biosciences on 5 of the 9 factors compared between the two stocks.

About Covalon Technologies

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company’s platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity. It also offers medical coating platform, a process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device. In addition, the company provides wound care dressings; surgical and peri-operative; and infection management products. It offers its products under the Covalon brand name through third-party distribution networks and company’s direct sales force. The company serves hospitals, wound care centers, burn centers, extended/alternate care and acute care facilities, home health care agencies, and physicians’ offices. Covalon Technologies Ltd. is headquartered in Mississauga, Canada.

About Pulse Biosciences

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.